Abstracts tagged "giant cell arteritis and large vessel vasculitis"

Abstract Number: 1704 • 2019 ACR/ARP Annual Meeting
Efficacy of Leflunomide for Treatment of Vasculitis
NOURA MUSTAPHA ¹, Lillian Barra ², Simon Carette ³, David Cuthbertson ⁴, Nader A. Khalidi ⁵, Curry L. Koening ⁶, Carol Langford ⁷, Carol McAlear ⁸, Nataliya Milman ⁹, Larry Moreland ¹⁰, Paul Monach ¹¹, Philip Seo ¹², Ulrich Specks ¹³, Antoine Sreih ¹⁴, Steven Ytterberg ¹³, Peter Merkel ¹⁴, Christian Pagnoux¹⁵, CanVasc Canadian Vasculitis Research Network ¹⁶ and VCRC Vasculitis Clinical Research Consortium ⁸, ¹Hopital Notre Dame, Montreal, QC, Canada, ²St Joseph's health care, London, Canada, ³Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Utah Hospital, Salt Lake City, UT, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Division of Rheumatology, Philadelphia, ⁹Arthritis Centre at the Ottawa Hospital, Riverside Campus, Ottawa, Canada, ¹⁰University of Pittsburgh, PITTSBURGH, PA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Johns Hopkins Medicine, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴University of Pennsylvania, Philadelphia, PA, ¹⁵Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹⁶Mount Sinai Hospital, Vasculitis clinic, toronto, ON, Canada
Background/Purpose: Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in ANCA-associated vasculitis and other…
Abstract Number: 2647 • 2019 ACR/ARP Annual Meeting
Flares and Long-term Remission in Large-vessel Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-term Follow-up Study
Carlo Salvarani¹, Luigi Boiardi ², Alberto Cavazza ³, Massimiliano Casali ⁴, Lucia Spaggiari ⁵, Luca Cimino ⁶, Raffaella Aldigeri ⁷, Francesco Muratore ⁸, Giovanna Restuccia ⁸, Nicolò Pipitone ⁵ and Pierluigi Macchioni ⁵, ¹Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Emilia-Romagna, Italy, ²Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³Pathology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, ⁵Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ⁶Ophthalmology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁷Università degli Studi di Parma, Parma, ⁸Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: To evaluate the frequency, timing, and characteristics of flares and to evaluate the frequency of long-term remission after glucocorticoids (GCs) suspension in an Italian…
Abstract Number: 2671 • 2019 ACR/ARP Annual Meeting
PET/CT Vascular Findings at Baseline and Six Months in Patients with Newly Diagnosed Giant Cell Arteritis
Anthony Sammel¹, Edward Hsiao ¹, Geoff Schembri ¹, Elizabeth Bailey ¹, Katherine Nguyen ¹, Janice Brewer ¹, Beatrice Janssen ¹, Leslie Schrieber ¹, Peter Youssef ², Clare Fraser ³ and Rodger Laurent ¹, ¹Royal North Shore Hospital, Sydney, Australia, ²Royal Prince Alfred Hospital, Sydney, Australia, ³Save Sight Institute, Sydney, Australia
Background/Purpose: PET/CT is a useful modality to diagnose GCA but there is limited knowledge as to how inflammatory vascular findings evolve on follow-up scans. This…
Abstract Number: 811 • 2017 ACR/ARHP Annual Meeting
The Presence of Giant Cells in the Temporal Artery Biopsy Is Associated with Reduced Risk of Future Large Vessel Involvement in Patients with Biopsy-Proven Giant Cell Arteritis
Nazanin Naderi^1,2, Aladdin Mohammad^3,4,5, Minna Willim^4,6, Jan-Åke Nilsson^1,6 and Carl Turesson^1,6, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology, Danderyd Hospital, Stockholm, Sweden, ³Department of Renal Medicine, Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁵Department of Rheumatology, Skåne University Hospital, Lund, Sweden, ⁶Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
Background/Purpose: Giant cell arteritis (GCA) is a systemic disease with extensive vascular involvement. The mechanisms underlying the diversity of GCA phenotypes are incompletely understood. The…
Abstract Number: 863 • 2016 ACR/ARHP Annual Meeting
Arterial Lesions in Giant Cell Arteritis
Tanaz A. Kermani¹, Sehriban Diab², Antoine Sreih³, David Cuthbertson⁴, Renee Borchin⁵, Simon Carette⁶, Lindsy J. Forbess⁷, Gary S. Hoffman⁸, Curry L. Koening⁹, Carol A. McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Christian Pagnoux¹³, Philip Seo¹⁴, Robert F. Spiera¹⁵, Kenneth J. Warrington¹⁶, Steven R. Ytterberg¹⁷, Carol A. Langford¹⁸, Nader A. Khalidi¹⁹ and Peter A. Merkel²⁰, ¹Rheumatology, University of California Los Angeles, Santa Monica, CA, ²St. Joseph’s Healthcare, McMaster University, Hamilton, ON, Canada, ³Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵University of South Florida, Tampa, FL, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ⁹Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology, Boston University School of Medicine, Boston, MA, ¹²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ¹⁴Medicine, Johns Hopkins University, Baltimore, MD, ¹⁵Hospital for Special Surgery, Cornell, New York, NY, ¹⁶Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ¹⁷Rheumatology, Mayo Clinic, Rochester, MN, ¹⁸Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁹Division of Rheumatology, St. Joseph’s Health Care, McMaster University, Hamilton, ON, Canada, ²⁰Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: This study aimed to describe large arterial lesions among patients with giant cell arteritis (GCA) and to understand what clinical characteristics are associated…
Abstract Number: 1968 • 2015 ACR/ARHP Annual Meeting
Distinct Distribution Patterns of Large Vessel Vasculitis Assessed with 18f-FDG PET/CT: Evidence from Principal Component and Cluster Analyses
Alessandra Soriano¹, Giulia Pazzola¹, Pierluigi Boiardi¹, Francesco Muratore¹, Pierluigi Macchioni¹, Raffaella Aldigeri², Massimiliano Casali³, Annibale Versari³ and Carlo Salvarani^1,4, ¹Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy, ³Nuclear Medicine Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ⁴Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, and University of Modena and Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: The performance of 18F-FDG PET/CT in the diagnosis and assessment of disease activity of LVV has not been fully established. The interpretation of data…
Abstract Number: 1689 • 2013 ACR/ARHP Annual Meeting
Antiplatelet Agents Decrease Ischemic Complications In Systemic Large Vessel Vasculitides: A Meta-Analysis
James Jeong¹ and Lillian J. Barra², ¹Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada, ²Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: Large Vessel Vasculitides (LVV) consist of Giant Cell Arteritis and Takayasu’s Arteritis, which are chronic systemic autoimmune diseases characterized by inflammation of large blood…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].